Venous thromboembolic risk and its prevention in hospitalized medical patients

被引:38
作者
Haas, SK [1 ]
机构
[1] Tech Univ Munich, Inst Expt Onkol & Therapieforsch, D-81675 Munich, Germany
关键词
venous thrombosis; pulmonary embolism; medical patients; thromboprophylaxis; low-molecular-weight heparins;
D O I
10.1055/s-2002-36702
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In medical patients, the risk of venous thromboembolism (VTE) is substantially underestimated and prophylaxis is used far less than in surgical patients, reflecting the scarcity of evidence supporting antithrombotic therapy in nonsurgical settings. However, current consensus documents recommend assessment of all medical, as well as surgical, patients for thromboembolic risk and provide prophylaxis recommendations according to the risk level, determined by the presence of different clinical and molecular risk factors. Although long-term, underlying clinical and molecular risk factors also have a major impact on overall risk in medical patients; risk clearly varies with the type of medical condition. Myocardial infarction, stroke, and malignant disease are linked to a high rate of VTE; recent evidence highlights patients with cardiopulmonary, disease as a distinct risk group. Despite skepticism in some quarters, high-quality evidence confirms the efficacy of unfractionated heparin (UFH) and low-molecular-weight heparins (LMNVH) in reducing asymptomatic deep vein thrombosis (DVT) in a broad spectrum of medical patients; further studies are required to clarify the effect on fatal pulmonary embolism (PE). Emerging data from the recent PRINCE and MEDENOX studies demonstrate that the LMWH enoxaparin provides effective and well-tolerated VTE prevention in patients with severe cardiopulmonary, disease. Emerging evidence has led to a grade 1A recommendation for the use of thromboprophylaxis in these patients in the most recent consensus conference on thromboprophylaxis. Further studies, however, are required to clarify the optimal duration of prophylaxis in medical patients and to evaluate the potential role of outpatient prophylaxis. Accurate risk assessment and prompt implementation of appropriate prophylaxis, selected on the basis of evidence from well-designed controlled clinical trials, may reduce the future morbidity and mortality due to VTE in medical patients.
引用
收藏
页码:577 / 583
页数:7
相关论文
共 50 条
[1]  
*2 THROMB RISK FAC, 1999, PHLEBOLOGY, V13, P87
[2]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[3]   PHYSICIAN PRACTICES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
FORCIER, A ;
PATWARDHAN, NA .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (08) :591-595
[4]   THE EFFECT OF DICUMAROL UPON THE MORTALITY AND INCIDENCE OF THROMBOEMBOLIC COMPLICATIONS IN CONGESTIVE HEART FAILURE [J].
ANDERSON, GM ;
HULL, E .
AMERICAN HEART JOURNAL, 1950, 39 (05) :697-702
[5]   Fatal pulmonary embolism in hospitalised medical patients [J].
Baglin, TP ;
White, K ;
Charles, A .
JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (07) :609-610
[6]   PREVENTION OF DEEP-VEIN THROMBOSIS IN MEDICAL PATIENTS BY LOW-DOSE HEPARIN [J].
BELCH, JJ ;
LOWE, GDO ;
WARD, AG ;
FORBES, CD ;
PRENTICE, CRM .
SCOTTISH MEDICAL JOURNAL, 1981, 26 (02) :115-117
[7]   Heparin prophylaxis in bedridden patients [J].
Bergmann, JF ;
Caulin, C .
LANCET, 1996, 348 (9021) :205-206
[8]  
Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529
[9]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[10]   Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism [J].
Bick, RL .
DRUGS, 2000, 60 (03) :575-595